Challenging clinical cases in HCV infection

BMC Infectious Diseases

Case Report

Patrizia Doldo¹  Francesco Manti²  Alfredo Focà³  Giovanni Matera³  Maria Carla Liberto³  Aida Giancotti³  Francesco Cesario⁴  Francesco Quintieri⁵  Lucio Cosco⁵  Selma Valerie Mammone⁶  Alessio Strazzulla⁶  Chiara Costa⁶  Vittoria Vaccaro⁶  Vincenzo Pisani⁶  Carlo Torti⁷ 

[1] Centre for Oncology, "Tommaso Campanella" Fundation, Catanzaro, Italy;Department of Radiology, "Magna Graecia" University of Catanzaro, Catanzaro, Italy;Institute of Microbiology, Department of Health Sciences, "Magna Graecia" University of Catanzaro, Catanzaro, Italy;Unit of Infectious Diseases, "Annunziata" Hospital, Cosenza, Italy;Unit of Infectious Diseases, "Pugliese-Ciaccio" Hospital, Catanzaro, Italy;Unit of Infectious Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy;Unit of Infectious Diseases, Department of Medical and Surgical Sciences, University "Magna Graecia", Catanzaro, Italy;University Unit of Infectious Diseases, University of Brescia, School of Medicine, Brescia, Italy;

关键词: HCC;    Hydatidosis;    Echinococcosis;    HCV;    Interferon;    Thalassemia;    Sickle cell disease;   

DOI  :  10.1186/1471-2334-14-S5-S7

来源: Springer

【 摘 要 】

We present clinical cases, which underline some difficulties in diagnosis and treatment of hepatitis C virus (HCV) infection. Case report #1 shows a patient who avoided clinical follow-up for HCV until the development of hepatocellular carcinoma. In this patient, non-invasive procedures did not allow to make a differential diagnosis between hydatidosis and hepatocellular carcinoma but diagnosis was only made with liver biopsy.In the case report #2, 24-week treatment with peg-interferon α2 and ribavirin was successfully administered to a HCV genotype-1b infected patient. Shortening HCV treatment did not impair sustained virological response, probably because HCV RNA was low (< 200,000 IU/l) at baseline.Lastly, a case series of patients (#3-6) with hemoglobinopathies is described. Sustained virological response after peg-interferon α2 and ribavirin was achieved in 2 out of 4 patients. While no severe treatment limiting hematological effects were encountered, patients needed more frequent blood transfusions. Thus, new anti-HCV schemes without peg-interferon and ribavirin are urgently needed.

【 授权许可】

Unknown   
© Strazzulla et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.